Literature DB >> 29516957

Dynamic changes of T-cell subsets and their relation with tumor recurrence after microwave ablation in patients with hepatocellular carcinoma.

Yan Zhou1, Xiaolin Xu2, Jianmin Ding1, Xiang Jing1, Fengmei Wang3, Yandong Wang1, Peng Wang4.   

Abstract

AIMS: Thermal ablation can evoke an immune response, which may have effects on the prognosis of patients with hepatocellular carcinoma (HCC). Our aim is to investigate the changes of circulating T-cell subsets after microwave ablation (MWA) and to explore the risk factors of tumor recurrence in patients with hepatitis B virus (HBV)-related HCC.
METHODS: Thirty patients with HBV-related HCC were enrolled in this study. The blood samples were collected both before and after MWA (24 h, 72 h, and 1 month after MWA). The distributions of Th17 cells, regulatory Treg-cells, CD4+ T-cells, CD8+ T-cells, and CD3+ T-cells were determined by flow cytometer. The potential-related factors of tumor recurrence were analyzed by logistic regression.
RESULTS: The levels of circulating T-cell subsets, except for Th17 cells, were relatively stable after MWA. The frequency of Th17 cells increased from 3.98% ± 2.40% before treatment to 5.53% ±3.27% 24 h after treatment. Eight of 30 patients had a tumor recurrence. The results of logistic regression suggested that among 11 candidates, only the level of Th17 cells was the risk factor of tumor recurrence. To remove the interference from other factors, seven patients with tumor(s) >3 cm or alpha-fetoprotein >400 ng/mL were excluded in another parallel logistic regression. The results of such regression clearly demonstrated that circulating Th17 cells is indeed a related factor of tumor recurrence.
CONCLUSIONS: Thermal ablation may evoke a transitional immune response by increasing the frequency of Th17 cells. Patients with high levels of baseline circulating Th17 cells, instead of the transient elevation of Th17 cells induced by MWA, are at the risk of tumor recurrence.

Entities:  

Keywords:  Hepatitis B virus; T lymphocytes; hepatocellular carcinoma; immunology; microwave ablation; tumor recurrence

Mesh:

Substances:

Year:  2018        PMID: 29516957     DOI: 10.4103/jcrt.JCRT_775_17

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  8 in total

Review 1.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

Review 2.  Innate immune cells and their interaction with T cells in hepatocellular carcinoma.

Authors:  Guo-Qing Hong; Dong Cai; Jian-Ping Gong; Xing Lai
Journal:  Oncol Lett       Date:  2020-11-19       Impact factor: 2.967

3.  Aberrant Alteration of Circulating Lymphocyte Subsets in Small Cell Lung Cancer Patients Treated with Radiotherapy.

Authors:  Hui Li; Hong Yu; Shaowei Lan; Dandan Zhao; Yan Liu; Ying Cheng
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

4.  Changes in immune profile affect disease progression in hepatocellular carcinoma.

Authors:  Farshid Fathi; Reza F Saidi; Hamid Reza Banafshe; Mohsen Arbabi; Majid Lotfinia; Hossein Motedayyen
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.219

5.  Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.

Authors:  Fei Yang; Gui-Li Xu; Jin-Tao Huang; Yu Yin; Wei Xiang; Bin-Yan Zhong; Wan-Ci Li; Jian Shen; Shuai Zhang; Jun Yang; Hong Peng Sun; Wan-Sheng Wang; Xiao-Li Zhu
Journal:  Front Immunol       Date:  2022-02-18       Impact factor: 7.561

Review 6.  Hepatocellular Carcinoma Intrinsic Cell Death Regulates Immune Response and Prognosis.

Authors:  Valli De Re; Anna Rossetto; Alessandro Rosignoli; Elena Muraro; Vito Racanelli; Maria Lina Tornesello; Aron Zompicchiatti; Alessandro Uzzau
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

Review 7.  Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors.

Authors:  Kanishka Rangamuwa; Tracy Leong; Clare Weeden; Marie-Liesse Asselin-Labat; Steven Bozinovski; Michael Christie; Tom John; Phillip Antippa; Louis Irving; Daniel Steinfort
Journal:  Transl Lung Cancer Res       Date:  2021-06

Review 8.  Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future.

Authors:  Matthias Ocker; Christian Mayr; Tobias Kiesslich; Sebastian Stintzing; Daniel Neureiter
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.